Blog

While the incidence of cancer in rural India is nearly half of that of urban India, the mortality rates are double due to the lack of adequate healthcare facilities, awareness about cancer and its risk factors, and limited access to cancer screening and treatment services.

Many cancer patients in India remain largely unaware of clinical trials. However, the recent infrastructural advancements in the local private hospitals make India an ideal platform for conducting clinical trials.

Earlier last year, Oncoshot India signed an MOU with the Basavatarakam Indo-American Cancer Hospital (BIACH) in May. The hospital’s objective is to serve the community and is run on a not-for-profit basis. It is a national-level healthcare institution specialising in cancer capabilities in research and education.

Our goal is to positively impact five million cancer patients globally, but we have recognised that we are also building a platform to support the development of tens, ideally hundreds, of drugs in the long term.

The awards celebrate the achievements of businesses and individuals who are leaders in their fields.

As a provider of clinical development services across all clinical trial phases and therapeutic areas, Novotech will leverage the Oncoshot platform to understand matching populations across key clinical trial markets in the APAC region.

Oncoshot has just announced one of its biggest collaborations to date with Icon Cancer Centre in Singapore, alongside Roche. Together the partners plan to facilitate more comprehensive genomic profiling data to increase access to more trial options for cancer patients.

Oncoshot has established a strategic partnership with Novartis to leverage its Project EISE platform which has the potential to enable more patients to access clinical trials in Singapore. EISE (pronounced as ‘easy’), an acronym for ‘Enhanced Clinical Trial Initiation, Screening and Enrolment,’ is a nationwide collaborative effort that connects cancer patients through an integrated, state-of-the-art care system. 

Check out this insightful video interview of our CEO and Co-Founder Huren Sivaraj about our recent partnership with Omico, the Australian Genomic Medicine Centre. Here he discusses the priorities in the Australian clinical trial ecosystem and the current challenges Oncoshot aims to address.

Oncoshot has just entered into a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre. The respective parties were represented at the event yesterday by Dr Huren Sivaraj, CEO and co-founder of Oncoshot, and Prof David Thomas, CEO of Omico and head of Genomic Cancer Medicine at the Garvan Institute.

Oncoshot today announced a pre-series A funding round led by MassMutual Ventures (MMV). Other investors for this stage come from a suite of healthtech veterans that include Milltrust International and health industry angel investors.

Oncoshot has signed a memorandum of understanding with the Singapore Clinical Research Institute (SCRI), the national coordinating body for clinical trials under the newly launched Consortium for Clinical Research and Innovation Singapore (CRIS). The signing event held last Wednesday was witnessed by guest-of-honour Minister for Health Mr Ong Ye Kung.

SINGAPORE, March 22, 2022 /PRNewswire/ – Oncoshot has announced it will be welcoming Dr Bernard Ng, Chief Scientific Officer of Milltrust Ventures, to its advisory board this month. This comes as a first step as the specialist investment organization finances the fast-growing health tech company founded in Singapore.

AstraZeneca will tap into Oncoshot’s data analytic capabilities of InSite Feasibility to introduce more relevant and innovative cancer clinical trials to Singapore.  

Public and private sectors in Singapore are harnessing genomic data through technologies such as Artificial Intelligence to advance the field of precision oncology.

Similar PD-1 inhibitors have been shown to improve the five-year survival rate of patients with advanced non-small cell lung cancer.

Experts including Dr Mothi Babu Ramalingam from Singapore General Hospital weighed in on breast cancer rehabilitation options in Singapore, including TCM.

The multi-centre Singapore study offers active surveillance to patients at high risk of developing liver cancer, with the aim of developing more accurate miRNA diagnostics for early HCC.

The therapy being trialled combines Toripalimab, an anti-PD1 immunotherapy drug developed in China, together with Bevacizumab.

Tech professional Amy Neary drew on emotional support from her family, friends and Singapore’s Breast Cancer Foundation to cope with the rigorous treatments and surgeries, plus the toll they took on her mental well-being.